Influence of β2-adrenoceptor polymorphisms on the response to chronic use of albuterol in asthmatic children
Autor: | Claudio Castaños, Verónica Giubergia, Mario Grenoville, Lilien Chertkoff, Luis Pablo Gravina |
---|---|
Rok vydání: | 2008 |
Předmět: |
Male
Pulmonary and Respiratory Medicine medicine.medical_specialty Time Factors Adolescent Genotype medicine.drug_class medicine.medical_treatment Population Argentina Forced Expiratory Volume Internal medicine Bronchodilator Humans Medicine Albuterol Prospective Studies Child education Asthma Desensitization (medicine) education.field_of_study Polymorphism Genetic business.industry Respiratory disease Drug Tolerance medicine.disease Bronchodilator Agents Endocrinology El Niño Spirometry Pediatrics Perinatology and Child Health Salbutamol Population study Female Receptors Adrenergic beta-2 business medicine.drug |
Zdroj: | Pediatric Pulmonology. 43:421-425 |
ISSN: | 1099-0496 8755-6863 |
Popis: | Background Several studies have suggested that after regular use of short acting β2-agonists the bronchodilator effect of the drug may decline and this condition would be related to polymorphisms of the β2-adrenergic receptor (β2-AR). Objective To assess the frequency of β2-AR polymorphisms in asthmatic children from Argentina, and to evaluate their influence on bronchodilator desensitization to albuterol over a 4-week treatment. Methods β2-AR genotypes were determined in 117 children with asthma and 101 of them were under 4 weeks treatment with albuterol. Spirometric changes in FEV1 were recorded at the beginning (day 1) and at the end of the study (day 30) and compared to genotypes at position 16 and 27 of the receptor. The frequency of the polymorphisms was calculated in all population. Results The presence of glutamine at position 27 (Gln27) was significantly more frequent in this Argentinean study population than in other Caucasian populations. The homozygosity for Gln27 polymorphism was associated to a desensitization of the receptor with a decline in the bronchodilator response to albuterol after chronic use. Conclusion Gln27 polymorphism might be a marker for adverse clinical outcomes with chronic β2-agonist exposure in children with asthma from Argentina. Pediatr Pulmonol. 2008; 43:421–425. © 2008 Wiley-Liss, Inc. |
Databáze: | OpenAIRE |
Externí odkaz: |